Beam Therapeutics Inc.

As of June 30, 2026, Beam Therapeutics, Inc. carries a market capitalization of 64.39B, placing it among publicly traded companies globally. Its enterprise value stands at 48.57B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Beam Therapeutics, Inc.'s next confirmed earnings release is scheduled for November 9, 2026.

As of June 30, 2026, Beam Therapeutics, Inc. has 103.26M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 23.62, and the price-to-book ratio stands at 3.45.

These figures are as of June 30, 2026. The EV/Sales ratio of 17.82 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 48.57B versus a market cap of 64.39B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Beam Therapeutics, Inc. maintains a current ratio of 14.57, meaning it holds 14.6x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Beam Therapeutics, Inc. posted a negative return on equity (ROE) of -8.08, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -6.15, reflecting losses generated across the asset base. The company generates approximately 5.41M in revenue per employee across its workforce of 504.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Beam Therapeutics, Inc. recorded an income tax benefit of -7.95M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -1.50B and -1.49B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Beam Therapeutics, Inc.'s stock has declined approximately 16.69% over the past 52 weeks.

Over the twelve months ended June 30, 2026, Beam Therapeutics, Inc. generated 2.73B in revenue and converted that into -1.49B in net income, yielding earnings per share of -14.38. EBITDA reached -6.22B, while operating income came in at -6.60B.

As of June 30, 2026, Beam Therapeutics, Inc. holds 20.14B in cash and equivalents against 4.32B in total debt, resulting in a net debt position of -2.09B. Total book value stands at 18.65B, with working capital of 19.18B providing operational flexibility.

Beam Therapeutics, Inc. produced -6.28B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -233.96M in capital expenditures, free cash flow totaled -6.51B - equivalent to -63.07 per share.

These figures cover the twelve months ended June 30, 2026. The operating margin of -242.27 and net profit margin of -54.75 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -10.06: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -2.92, meaning Beam Therapeutics, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Beam Therapeutics, Inc. has an Altman Z-Score of 5.22, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.